Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments.
The mucoid exopolysaccharide (MEP or alginate) of Pseudomonas aeruginosa is thought to be a virulence factor for this organism by virtue of its ability to suppress local host defense mechanisms. We purified MEP from clinical isolates of mucoid P. aeruginosa, subjected it to degradation by ultrasonication, heat, alkali, and alginase, and reacted it with monoclonal antibodies specific for MEP epitopes. Partial reversal or complete abrogation of the inhibitory effects of alginate on human neutrophil random migration, chemotaxis, and hexose monophosphate shunt activity and lymphocyte transformation were observed following most of these treatments. Physicochemical analysis of degraded MEP revealed a positive correlation between changes in molecular size and viscosity and loss of biological properties. The biological properties of MEP were also shown to be dependent on the structural integrity of the O-acetyl groups substituted for the mannuronic acid residues. The results show that the capacity of MEP to suppress neutrophil and lymphocyte functions is dependent on its acetyl content and the physical properties of large size and viscosity and may provide part of the explanation for the propensity of mucoid P. aeruginosa to persist in the airways of patients with cystic fibrosis. These findings highlight the important role of MEP as one of the virulence factors in the pathogenesis of inflammatory damage and subsequent pulmonary destruction in cystic fibrosis.
Mai
G T
GT
Department of Child Health, University of Queensland, Mater Public Hospital, South Brisbane, Australia.
Seow
W K
WK
Pier
G B
GB
McCormack
J G
JG
Thong
Y H
YH
D000464:Alginates / Q000378:metabolism / Q000633:toxicity*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D020723:Glucuronic Acid; D006026:Glycoside Hydrolases / Q000494:pharmacology*; D006603:Hexuronic Acids; D006801:Humans; D007166:Immunosuppressive Agents / Q000633:toxicity*; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D011133:Polysaccharide-Lyases; D011135:Polysaccharides, Bacterial / Q000378:metabolism / Q000633:toxicity*; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity*; D014774:Virulence
D000464:Alginates; D000911:Antibodies, Monoclonal; D006603:Hexuronic Acids; D007166:Immunosuppressive Agents; D011135:Polysaccharides, Bacterial; C064841:exopolysaccharide, Pseudomonas; D020723:Glucuronic Acid; D006026:Glycoside Hydrolases; D011133:Polysaccharide-Lyases; C016158:poly(beta-D-mannuronate) lyase